I imagine the next trial will have a primary end point of death reduction in under 65s due covid, and exploratory end points of different doses in over 65's...... and maybe, just maybe also all cause ARDS as a secondary exploratory end point also.
Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients, page-27
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
90.0¢ |
Change
-0.070(7.22%) |
Mkt cap ! $1.033B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 95.0¢ | 90.0¢ | $7.467M | 8.132M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 32412 | 90.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 90.5¢ | 231517 | 37 |
View Market Depth
| Last trade - 14.52pm 05/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |